Loading clinical trials...
Loading clinical trials...
An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Conditions
Interventions
Nivolumab
Elotuzumab
+2 more
Locations
121
United States
Local Institution - 0020
Birmingham, Alabama, United States
Local Institution - 0160
Mobile, Alabama, United States
Local Institution - 0163
Fayetteville, Arkansas, United States
Local Institution - 0118
Bakersfield, California, United States
Local Institution - 0093
Corona, California, United States
Local Institution - 0016
Fountain Valley, California, United States
Start Date
August 10, 2016
Primary Completion Date
March 9, 2022
Completion Date
March 9, 2022
Last Updated
March 27, 2023
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06870760
NCT06057402
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions